Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer

American Journal of Managed Care

Volumn 11, Issue 5, 2005, Pages 313-324

  Hornberger, John ^a,b,c,g   Cosler, Leon E ^d   Lyman, Gary H ^e,f  

^a Acumen LLC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE DERIVATIVE; ESTROGEN RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COST; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; ECONOMIC ASPECT; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG THERAPY; HUMANS; LYMPH NODES; MARKOV CHAINS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 18444374426     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Jemal A, Tiwari R, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-942.
3. Muss HB. Adjuvant therapy for older women with breast cancer. Breast. 2003;12:550-557.
4. Bergh J. Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsiveness. Breast. 2003;12:529-537.
5. Cardoso F, Piccart MJ. The best use of chemotherapy in the adjuvant setting. Breast. 2003;12:522-528.
6. Pritchard KI. The best use of adjuvant endocrine treatments. Breast. 2003;12: 497-508.
7. Piccart MJ, Sotiriou C, Cardoso F. New data on chemotherapy in the adjuvant setting. Breast. 2003;12:373-378.
8. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus. Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001;19:3817-3827.
9. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357-3365.
10. Palazzi M, De Tomasi D, D'Affronto C, et al. Are international guidelines for the prescription of adjuvant treatment for early breast cancer followed in clinical practice? Results of a population-based study on 1547 patients. Tumori. 2002;88: 503-506.
11. Senn HJ, Thurlimann B, Goldhirsch A, et al. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast. 2003;12:569-582.
12. Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med. 2003;163:2149-2153.
13. Ernst MF, Voogd AC, Coebergh JW, Roukema JA. Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening. Cancer. 2004;100:1337-1344.
14. McCarthy EP, Burns RB, Coughlin SS, et al. Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women. Ann Intern Med. 1998;128:729-736.
15. Kassirer JP, Pauker SG. The toss-up. N Engl J Med. 1981;305:1467-1469.
16. Davies C, McGale P, Peto R. Variation in use of adjuvant tamoxifen. Lancet. 1998;351:1487-1488.
17. Buban GM, Link BK, Doucette WR. Influences on oncologists' adoption of new agents in adjuvant chemotherapy of breast cancer. J Clin Oncol. 2001;19:954-959.
18. Stiggelbout AM, de Haes JC, van de Velde CJ. Adjuvant chemotherapy in node negative breast cancer: patterns of use and oncologists' preferences. Ann Oncol. 2000;11:631-633.
19. Nagel G, Rohrig B, Hoyer H, Wedding U, Katenkamp D. A population-based study on variations in the use of adjuvant systemic therapy on postmenopausal patients with early stage breast cancer. J Cancer Res Clin Oncol. 2003;129:183-191.
20. Harlan LC, Abrams J, Warren JL, et al. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002;20:1809-1817.
21. Bickell NA, McEvoy MD. Physicians' reasons for failing to deliver effective breast cancer care: a framework for underuse. Med Care. 2003;41:442-446.
22. Brenton JD, Caldas C. Predictive cancer genomics-what do we need? Lancet. 2003;362:340-341.
23. Titus K. Reclassifying cancer, guided by genomics. CAP Today. 2001;15:1, 14-16,
24. Available at: http://www.cap.org. Accessed December 14, 2004.
25. Ince TA, Weinberg RA. Functional genomics and the breast cancer problem. Cancer Cell. 2002;1:15-17.
26. Mariani SM. Functional genomics: improving cancer prognosis and drug development. Medscape General Medicine: Hematology-Oncology 2003;5(1). Available at: http://www.medscape.com/viewarticle/450095. Accessed December 14, 2004.
27. Bisca A, D'Ambrosio C, Scaloni A, et al. Proteomic evaluation of core biopsy specimens from breast lesions. Cancer Lett. 2004;204:79-86.
28. Garber K. Genomic medicine. Gene expression tests foretell breast cancer's future. Science. 2004;303:1754-1755.
29. Paik S, Shak S, Tang C, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
30. Paik S, Shak S, Tang C, et al. Risk classification of breast cancer patients by the Recurrence Score assay: comparison to guidelines based on patient age, tumor size, and tumor grade. Abstract presented at: 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, Tex. Abstract 104.
31. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
32. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001;358:277-286.
33. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004; 22:854-863.
34. Desch CE, Hillner BE, Smith TJ, Retchin SM. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol. 1993;11:777-782.
35. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med. 1991;324:160-168.
36. Chang J, Woolen E, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362-369.
37. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. Abstract presented at: American Society of Clinical Oncology (ASCO) 40th Annual Meeting; June 4-8, 2004; New Orleans, La. Abstract 501.
38. J Clin Oncol. 2004;22(suppl): Abstract 501. Available at: http://www.asco.org. Accessed December 14, 2004.
39. Paik S, Shak S, Tang G, et al. Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Abstract presented at: 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, Tex. Abstract 24.
40. Earle C, Chapman R, Baker C, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:3302-3317.
41. Love N, Ravdin P, Hortobagyi G, Grana G, Paley MF, Poltorack L, for the Breast Cancer Update Working Group. Influence of prior therapy on breast cancer survivors' preferences for adjuvant systemic therapy in hypothetical scenarios. Abstract presented at: American Society of Clinical Oncology (ASCO) 40th Annual Meeting; June 4-8, 2004; New Orleans, La. Abstract 591.
42. J Clin Oncol. 2004;22 (suppl): Abstract 591. Available at: http://www.asco.org. Accessed December 14, 2004.
43. 2003 Drug Topics Red Book: The Pharmacist's Trusted Companion for More Than a Century. Montvale, NJ: Thomson Healthcare; 2003.
44. National Comprehensive Cancer Network. Breast Cancer, Version 1. Clinical Practice Guidelines in Oncology, v.1.2005. Jenkintown, Penn: National Comprehensive Cancer Network, Inc; 2005. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/breast.pdf. Accessed April 5, 2005.
45. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev. 1997;18(4):51-76.
46. Hogan C, Lunney J, Gabel J, Lynn J. Medicare beneficiaries' costs of care in the last year of life. Health Aff (Millwood). 2001;20(4):188-195.
47. Hoover DR, Crystal S, Kumar R, Sambamoorthi U, Cantor JC. Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res. 2002;37:1625-1642.
48. Nattinger AB. Quality of care for breast cancer. Med Care. 2003;41:341-343.
49. Kornblith AB, Herndon JE 2nd, Weiss RB, et al. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer. 2003;98:679-689.
50. Jansen SJ, Kievit J, Nooij MA, Stiggelbout AM. Stability of patients' preferences for chemotherapy: the impact of experience. Med Decis Making. 2001;21:295-306.
51. OncoSurvey.com. Breast cancer [survey]. Summary 4th quarter 2003. Details of survey design available at: http://www.oncosurvey.com/aboutoncosurvey.html. Accessed December 14, 2004.
52. Simon MS, Stano M, Hussein M, Hoff M, Smith D. An analysis of the cost of clinical surveillance after primary therapy for women with early stage invasive breast cancer. Breast Cancer Res Treat. 1996;37:39-48.
53. Lipscomb J, Weinstein M, Torrence G. Time preference. In: Gold M, Weinstein M, Lipscomb J, Torrence G, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:214-246.
54. NIH Consensus Development Program. Adjuvant Therapy for Breast Cancer. NIH Consensus Statement Online 2000 November 1-3;17(4):1-23. Consensus Statement 114. Available at: http://consensus.nih.gov/cons/114/114_intro.htm. Accessed December 14, 2004.
55. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6: 9-17.
56. Reinhardt UE, Hussey PS, Anderson GF. US health care spending in an international context. Health Aff (Millwood). 2004;23(3):10-25.
57. Garber A. Cost effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood) [serial online]. May 14, 2004; web exclusive:W4-284-W4-296. Available at: http://content.healthaffairs.org. Accessed December 14, 2004.
58. Singer SJ, Bergthold LA. Prospects for improved decision making about medical necessity. Health Aff (Millwood). 2001;20(1):200-206.
59. Smedley BD, Stith AY, Nelson AR, eds, and Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academy Press; 2003.
60. Gottlieb RH, Mooney C, Mushlin AI, Rubens DJ, Fultz PJ. The prostate: decreasing cost-effectiveness of biopsy with advancing age. Invest Radiol. 1996;31:84-90.
61. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991;325:81-86.
62. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163:1637-1641.
63. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1-31.
64. Bast RC Jr, Hortobagyi GN. Individualized care for patients with cancer-a work in progress. N Engl J Med. 2004;351:2865-2867.
65. Habel L, Quesenberry C, Jacobs M, et al. A large case-control study of gene expression and breast cancer death in the Northern California Kaiser Permanente population. Abstract presented at: 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, Tex. Abstract 3019. Available at: http://www.abstracts2view.com/sabes. Accessed April 5, 2005.
66. Bruera E, Willey JS, Palmer JL, Rosales M. Treatment decisions for breast carcinoma: patient preferences and physician perceptions. Cancer. 2002;94:2076-2080.
67. Roila F, Ballatori E, Patoia L, et al. Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. Ann Oncol. 2003;14:843-848.
68. Bloom BS, de Pouvourville N, Chhatre S, Jayadevappa R, Weinberg D. Breast cancer treatment in clinical practice compared to best evidence and practice guidelines. Br J Cancer. 2004;90:26-30.